PVT1 Promotes Angiogenesis by Regulating miR-29c/Vascular Endothelial Growth Factor (VEGF) Signaling Pathway in Non-Small-Cell Lung Cancer (NSCLC)

被引:39
作者
Mao, Zejun [1 ]
Xu, Botao [1 ]
He, Lixiang [1 ]
Zhang, Guodong [1 ]
机构
[1] Zhuji Peoples Hosp, Dept Cardiothorac Surg, Zhuji, Zhejiang, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2019年 / 25卷
关键词
Angiogenesis Inducing Agents; Carcinoma; Non-Small-Cell Lung; Vascular Endothelial Growth Factor A; BEVACIZUMAB; EXPRESSION; DISCOVERY; APOPTOSIS;
D O I
10.12659/MSM.917601
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Lung cancer is a common tumor. Non-small-cell lung cancer (NSCLC) accounts for over 85% of lung cancer and has a high degree of malignancy. Angiogenesis plays an important role in NSCLC progression. Some studies have found that PVT1 can promote angiogenesis in tumor tissues, but the role of PVT1 in angiogenesis in NSCLC, as well as the underlying mechanism, is unclear. Material/Methods: To explore the role of PVT1 in NSCLC, qRT-PCR, Western blot, luciferase reporter assay, and ELISA were carried out for detecting the relationship among PVT1, miR-29c, and VEGF. Tube formation assay was used to assess the role of PVT1 in angiogenesis in NSCLC. Results: Our results showed that higher PVT1 was expressed in NSCLC and the elevated PVT1 was closely related to angiogenesis and poor prognosis in NSCLC. Further functional analysis showed that higher PVT1 expression could promote angiogenesis by regulating VEGF in NSCLC. Mechanistically, the luciferase reporter assay confirmed that VEGF was the targeted gene of miR-29c. In addition, we found that miR-29c is an inhibitory target of PVT1. Conclusions: We found that PVT1 promotes angiogenesis through targeting the miR-29c/VEGF signaling pathway in NSCLC.
引用
收藏
页码:5418 / 5425
页数:8
相关论文
共 33 条
[1]   VEGF in Signaling and Disease: Beyond Discovery and Development [J].
Apte, Rajendra S. ;
Chen, Daniel S. ;
Ferrara, Napoleone .
CELL, 2019, 176 (06) :1248-1264
[2]   Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer [J].
Bear, Harry D. ;
Tang, Gong ;
Rastogi, Priya ;
Geyer, Charles E., Jr. ;
Robidoux, Andre ;
Atkins, James N. ;
Baez-Diaz, Luis ;
Brufsky, Adam M. ;
Mehta, Rita S. ;
Fehrenbacher, Louis ;
Young, James A. ;
Senecal, Francis M. ;
Gaur, Rakesh ;
Margolese, Richard G. ;
Adams, Paul T. ;
Gross, Howard M. ;
Costantino, Joseph P. ;
Swain, Sandra M. ;
Mamounas, Eleftherios P. ;
Wolmark, Norman .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04) :310-320
[3]   A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1 [J].
Buijs, Nikki ;
Oosterink, J. Efraim ;
Jessup, Morgan ;
Schierbeek, Henk ;
Stolz, Donna B. ;
Houdijk, Alexander P. ;
Geller, David A. ;
van Leeuwen, Paul A. .
ANGIOGENESIS, 2017, 20 (04) :557-565
[4]  
Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345
[5]   Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis and cancer biology [J].
Elaimy, Ameer L. ;
Mercurio, Arthur M. .
SCIENCE SIGNALING, 2018, 11 (552)
[6]   MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B [J].
Fabbri, Muller ;
Garzon, Ramiro ;
Cimmino, Amelia ;
Liu, Zhongfa ;
Zanesi, Nicola ;
Callegari, Elisa ;
Liu, Shujun ;
Alder, Hansjuerg ;
Costinean, Stefan ;
Fernandez-Cymering, Cecilia ;
Volinia, Stefano ;
Guler, Gulnur ;
Morrison, Carl D. ;
Chan, Kenneth K. ;
Marcucci, Guido ;
Calin, George A. ;
Huebner, Kay ;
Croce, Carlo M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (40) :15805-15810
[7]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[8]   Ten years of anti-vascular endothelial growth factor therapy [J].
Ferrara, Napoleone ;
Adamis, Anthony P. .
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (06) :385-403
[9]   Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression [J].
Gao, Dingcheng ;
Nolan, Daniel ;
McDonnell, Kevin ;
Vahdat, Linda ;
Benezra, Robert ;
Altorki, Nasser ;
Mittal, Vivek .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1796 (01) :33-40
[10]   Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis [J].
Hong, Shaodong ;
Tan, Min ;
Wang, Shouzheng ;
Luo, Shengyuan ;
Chen, Yue ;
Zhang, Li .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) :909-921